| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCND2 |
| Uniprot No | P30279 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-289aa |
| 氨基酸序列 | MELLCHEVDPVRRAVRDRNLLRDDRVLQNLLTIEERYLPQCSYFKCVQKDIQPYMRRMVATWMLEVCEEQKCEEEVFPLAMNYLDRFLAGVPTPKSHLQLLGAVCMFLASKLKETSPLTAEKLCIYTDNSIKPQELLEWELVVLGKLKWNLAAVTPHDFIEHILRKLPQQREKLSLIRKHAQTFIALCATDFKFAMYPPSMIATGSVGAAICGLQQDEEVSSLTCDALTELLAKITNTDVDCLKACQEQIEAVLLNSLQQYRQDQRDGSKSEDELDQASTPTDVRDIDL |
| 预测分子量 | 80.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCND2重组蛋白的3篇代表性文献的简要信息：
---
1. **文献名称**：*"Recombinant CCND2 regulates cell cycle progression via CDK4/6 interaction in breast cancer cells"*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌表达重组CCND2蛋白，发现其与CDK4/6结合后可加速乳腺癌细胞G1/S期转化，提示其在肿瘤增殖中的潜在靶点作用。
---
2. **文献名称**：*"Structural characterization of human CCND2 recombinant protein and its phosphorylation sites"*
**作者**：Zhang L, et al.
**摘要**：利用昆虫细胞系统表达纯化CCND2重组蛋白，结合质谱分析揭示其Thr280位点的磷酸化修饰对蛋白稳定性及核定位的关键影响。
---
3. **文献名称**：*"CCND2 recombinant protein promotes β-cell regeneration in a diabetic mouse model"*
**作者**：Kim Y, et al.
**摘要**：通过腺病毒载体递送重组CCND2至胰腺，证实其可激活β细胞周期再进入，改善糖尿病模型小鼠的胰岛素分泌功能，为再生治疗提供新策略。
---
以上文献均为示例，实际引用时需核实具体来源及准确性。如需全文链接或补充信息，请进一步说明。
CCND2 (cyclin D2) is a regulatory protein involved in cell cycle progression, primarily governing the transition from the G1 phase to the S phase. As a member of the D-type cyclin family (CCND1. CCND2. CCND3), it forms complexes with cyclin-dependent kinases (CDK4/6) to phosphorylate and inactivate the retinoblastoma (Rb) protein, thereby releasing E2F transcription factors to drive DNA replication. Unlike CCND1. which is ubiquitously expressed, CCND2 shows tissue-specific activity, particularly in the immune, endocrine, and nervous systems. Its expression is tightly regulated by mitogenic signals, growth factors, and hormonal cues, with dysregulation linked to cancers, endocrine disorders, and neurological conditions.
Recombinant CCND2 proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to produce purified, functional proteins for research and therapeutic development. These proteins typically retain conserved cyclin domains critical for CDK binding and regulatory functions. Researchers employ recombinant CCND2 to study cell cycle mechanisms, cancer biology (e.g., lymphoma, breast cancer), and metabolic diseases, as its overexpression or deletion correlates with tumorigenesis and insulin resistance. In drug discovery, it serves as a tool to screen CDK4/6 inhibitors (e.g., palbociclib) or validate therapeutic targets. Additionally, recombinant CCND2 aids in structural studies (e.g., X-ray crystallography) to map interaction interfaces with CDKs or tumor-associated mutants. Despite challenges like post-translational modifications and stability, its role in tissue regeneration and disease pathways sustains translational interest.
×
